Intellipharmaceutics International Inc. (IPCI) Earns Buy Rating from Analysts at Brean Capital
Brean Capital initiated coverage on shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) in a report issued on Monday. The firm issued a buy rating and a $8.00 price objective on the stock.
IPCI has been the topic of several other reports. Zacks Investment Research raised Intellipharmaceutics International from a hold rating to a buy rating and set a $1.50 price objective on the stock in a report on Wednesday, June 15th. Maxim Group reaffirmed a buy rating on shares of Intellipharmaceutics International in a report on Friday, July 22nd.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) opened at 2.241 on Monday. Intellipharmaceutics International has a 12-month low of $1.41 and a 12-month high of $3.19. The company’s market cap is $64.42 million. The company has a 50-day moving average of $1.93 and a 200 day moving average of $1.83.
Intellipharmaceutics International (NASDAQ:IPCI) last issued its quarterly earnings data on Wednesday, July 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 325.20%. On average, equities research analysts expect that Intellipharmaceutics International will post ($0.28) EPS for the current year.
An institutional investor recently bought a new position in Intellipharmaceutics International stock. Atria Investments LLC purchased a new stake in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned about 0.27% of Intellipharmaceutics International as of its most recent filing with the SEC. 1.30% of the stock is owned by hedge funds and other institutional investors.
Intellipharmaceutics International Company Profile
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.